ETBX-011
AXP000154.1 · Cancer vaccine
- Platform
- adenovirus (Ad5 [E1-, E2b-])
- Targets
- CEACAM5
- Originator
- Etubics
- Sponsor
- ImmunityBio
Names
| Name | Type | Source |
|---|---|---|
| ETBX-011 | preferred name, code | curator, ncit |
| Ad5 CEA Vaccine ambiguous | synonym | ncit |
| Adenoviral Vector Ad5-CEA(6D) Vaccine ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 [E1-, E2b-]
- Replication
- non replicating
- Modifications
- E1 and E2b regions deleted (replication-defective, reduced late gene expression)
- Transgenes
- CEA(6D) (carcinoembryonic antigen with a modified CAP1-6D epitope)
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C91373
- FDA UNII
- RP9RQ0SOM8
Approvals
No regulatory approval recorded.
Clinical trials (20)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04247282 | Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection | Completed | Phase 1/2 | 2020-06-09 | 2021-08-24 | 21 | Head and Neck Cancer; Head and Neck Neoplasms |
| NCT03563157 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Terminated | Phase 1/2 | 2018-09-28 | 2019-04-21 | 2 | Colorectal Cancer Metastatic; mCRC |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Withdrawn | Phase 2 | 2018-09 | 2020-06 | 0 | Triple Negative Breast Cancer (TNBC) |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Withdrawn | Phase 2 | 2018-08 | 2019-12-30 | 0 | Metastatic Pancreatic Cancer |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | Withdrawn | Phase 1/2 | 2018-08 | 2019-01 | 0 | Colorectal Cancer |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Terminated | Phase 1/2 | 2018-07-17 | 2019-04-17 | 3 | Pancreatic Cancer |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | Withdrawn | Phase 2 | 2018-06 | 2018-08 | 0 | Non Small Cell Lung Cancer |
| NCT03563170 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | Withdrawn | Phase 1/2 | 2018-05-25 | 2019-08-23 | 0 | Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Terminated | Phase 1/2 | 2018-03-19 | 2020-09-11 | 9 | Triple Negative Breast Cancer |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | Withdrawn | Phase 1/2 | 2018-02 | 2019-01 | 0 | Non-small Cell Lung Cancer |
| NCT03384316 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer | Completed | Phase 1 | 2018-01-31 | 2018-05-22 | 11 | Breast Cancer; Colon Cancer; Lung Cancer; Neoplasms; Prostate Cancer |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | Terminated | Phase 1/2 | 2018-01-09 | 2019-04-17 | 4 | Squamous Cell Carcinoma |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Terminated | Phase 1/2 | 2017-12-28 | 2018-09-12 | 4 | Pancreatic Cancer |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-01 | 0 | Urothelial Carcinoma |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-01 | 0 | Triple Negative Breast Cancer |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-01 | 0 | Head and Neck Squamous Cell Carcinoma |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | Withdrawn | Phase 1/2 | 2017-12 | 2019-01 | 0 | Melanoma |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Terminated | Phase 1/2 | 2017-11-06 | 2018-08-13 | 6 | Pancreatic Cancer |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Terminated | Phase 1/2 | 2017-08-11 | 2017-11-22 | 3 | Pancreatic Cancer |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | Terminated | Phase 1/2 | 2017-06-26 | 2017-12-07 | 3 | Breast Cancer; Colon Cancer; Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Thyroid Cancer |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | Completed | Phase 1/2 | 2010-07-16 | 2017-05-31 | 43 | Breast Cancer; Colorectal Cancer; Lung Cancer; Prostate Cancer | intervention named: Ad5 CEA Vaccine |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40156838 | Tri-Ad5 vaccine plus bintrafusp alfa for newly diagnosed, advanced-stage head and neck cancer not associated with human papillomavirus infection. | The oncologist | 2025 | cited by trial NCT04247282 |
| PMID 35727629 | Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. | The Journal of clinical investigation | 2022 | cited by trial NCT04247282 |
| PMID 33720067 | The role of the tumor matrix environment in progression of head and neck cancer. | Current opinion in oncology | 2021 | cited by trial NCT04247282 |
| PMID 31594913 | A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. | The oncologist | 2020 | cited by trial NCT03384316 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 26374823 | The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. | Oncotarget | 2015 | name in abstract: ETBX-011 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: ETBX-011 |
| ZIABC010972 | Identification of human tumor-associated antigens | DIVISION OF BASIC SCIENCES - NCI | TSANG, KWONG YOK | 2009–2016 | name in abstract: ETBX-011 |
| R43CA186357 | Development of an Ad5-CEA/Brachyury Vector Approach for Cancer Treatment | ETUBICS CORPORATION | JONES, FRANK R. | 2014–2014 | name in abstract: ETBX-011 |
Notes
Ad5 [E1-, E2b-] vector of the Etubics (now ImmunityBio) AdenoVerse-style platform, given subcutaneously; the E2b deletion is intended to allow repeat dosing despite pre-existing Ad5 immunity. Studied alone and in the multi-antigen Tri-Ad5 / 'Triad' regimens, which are combinations and not programs of their own. NCIt preferred name: Ad5 [E1-, E2b-]-CEA(6D) Vaccine.
How to cite
ETBX-011 (AXP000154.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000154.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.